[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100511458":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":23,"locations":31,"responsibleParty":51,"collaborators":10,"id":53,"slug":10,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":59,"maxAge":10,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":10,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1",null,"Pregnant or breastfeeding women exposed to mavacamten",[13],"Drug: Mavacamten",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Mavacamten","Observational study of individuals exposed to at least 1 dose of mavacamten at any time during pregnancy and\u002For breastfeeding",[9],[21],{"name":5,"affiliation":5,"role":22},"STUDY_DIRECTOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"BMS Study Connect Contact Center www.BMSStudyConnect.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":30,"role":26,"phone":10,"phoneExt":10,"email":10},"First line of the email MUST contain NCT # and Site #.",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"The Mavacamten Pregnancy Surveillance Program, PPD Inc","RECRUITING","Wilmington","North Carolina","28401-3331","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-77.94604,34.23556,{"lat":44,"lon":43},[47],{"name":48,"role":26,"phone":49,"phoneExt":10,"email":50},"The Mavacamten Pregnancy Surveillance Program Resea PPD, Inc","877-390-2852","camzyospregnancysurveillanceprogram@ppd.com",{"type":52,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100511458",false,"NCT05939700","Mavacamten Pregnancy Surveillance Program","Inclusion Criteria:\n\n* Exposure to at least 1 dose of mavacamten at any time during pregnancy (from 4 months prior to conception to pregnancy outcome) and\u002For at any time during breastfeeding (up to 12 months of infant age or weaning, whichever comes first)\n* At least 15 years of age or older at the time of enrollment\n* Informed consent or institutional review board\u002Fethics committee-approved waiver of informed consent\n\nExclusion Criteria:\n\n\\- None","FEMALE","15 Years",{"count":61,"type":62},20,"ESTIMATED","OBSERVATIONAL","The purpose of this observational pregnancy safety study is to assess maternal, fetal, and infant outcomes after exposure to mavacamten at any time during pregnancy and\u002For breastfeeding.",[66,67,68],"Breastfeeding","Hypertrophic Cardiomyopathy","Pregnancy Related","2025-11-05",{"date":71,"type":72},"2025-11-06","ACTUAL",{"date":74,"type":72},"2023-11-09",{"date":76,"type":62},"2027-04-30",{"name":5,"class":6},1]